Swedish Orphan Biovitrum AB (publ)

Research Swedish Orphan Biovitrum AB (publ) (SOBI) on Bullrun: valuation model: 70.2% overvalued, market cap SEK 162.96B, P/E 178.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSOBI
• ExchangeST
• CountrySweden
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic
• CurrencySEK
• Valuation signal70.2% overvalued
• Market capSEK 162.96B
• P/E178.6
• Financial periodFY2024
• RevenueSEK 26.03B
• Revenue growth17.6%
• Net incomeSEK 3.88B
• Free cash flowSEK 7.22B
• Gross margin77.8%

Valuation Snapshot

Bullrun's latest valuation model marks Swedish Orphan Biovitrum AB (publ) as 70.2% overvalued; latest market cap is SEK 162.96B; P/E is 178.6.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria;

Frequently asked questions

Is Swedish Orphan Biovitrum AB (publ) overvalued or undervalued?

Bullrun's valuation model currently marks Swedish Orphan Biovitrum AB (publ) as 70.2% overvalued.

What is Swedish Orphan Biovitrum AB (publ)'s market cap?

Swedish Orphan Biovitrum AB (publ)'s market capitalization is SEK 162.96B.

What is Swedish Orphan Biovitrum AB (publ)'s P/E ratio?

Swedish Orphan Biovitrum AB (publ)'s price-to-earnings (P/E) ratio is 178.6.

What does Swedish Orphan Biovitrum AB (publ) do?

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care.